PDA Takes On Risks for Patients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PDA Takes On Risks for Patients
Risk management, and its benefits for patients, plays a big role at the PDA Annual Meeting.


Pharmaceutical Technology


Maribel Rios
The 2008 PDA Annual Meeting in Colorado Springs was a good example of how the organization has grown. As Ted Meltzer, a long-time friend and renowned professional, told me: "The PDA organization is now a powerhouse in processing information for the industry."

Consider, for example, how PDA has adopted risk management. Risk management used to be an abstract phrase no one really could define. This is no longer the case. Presenters discussed how risk management serves as a basis for process validation, the optimization of aseptic operations (e.g. Technical Report 44), and as an essential part of patient safety.

Will risk management principles continue to grow with PDA? "I hope so, as it might also have an influence on postapproval changes," says Maik Jornitz, chair of the 2008 planning committee. "[With a] risk-based approach on postapproval changes, maybe life could be a bit easier for innovative biopharmaceutical firms that want to introduce new production equipment into their processes. Former FDA Commissioner McClellan wished for a process improvement rate in biopharmaceutical processes similar to those in the semiconductor industry. This can only happen when regulatory authorities create the possibility for such requests. Maybe a risk-based approach would create such possibility."

Next year's meeting, which will focus on the impact of microchip technology, will expand on risk-management principles. According to Ian Elvins, chair of the 2009 planning committee, "The intention is to look at some of the many tools and techniques involving computers and automation, so clearly the adoption of a risk-based approach opens up many new possibilities that might not have been considered in the past. Not least will be techniques which use computers to directly evaluate risk to enable better decision-making."

Maribel Rios is a senior editor of Pharmaceutical Technology,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
28%
Attracting a skilled workforce
26%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
33%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here